20/20 HealthCare Partners LLC
Venture capitalAuburndale · Seed–Late Stage · 7 people tracked
Investment thesis
20/20 HCP invests at the early stage of life sciences and healthcare technology, targeting companies in diagnostic imaging, medical devices, healthcare IT, biotechnology and pharmaceuticals. It focuses on the phase after proof of concept has been established, funding program development through to the completion of verification and validation studies (pre-regulatory approval and pre-commercialization). It typically acts as lead investor providing managerial and operational support alongside capital, aiming for short investment periods of about 2-3 years to exit and returns in the 3-7x range, with exit routes including sale, licensing, partnership with big pharma, or a follow-on financing round.
Source: firm website, verified Aug 3, 2026.
Team · 7 people
from the firm's website & public directories
What they invest in
from 7 of 17 portfolio companiesHealthtech ×6Biotech ×4Digital Health ×2AI & Machine Learning ×1Cloud Computing ×1Media & Entertainment ×1Medical Devices ×1SaaS ×1
HQs:United States×6
Investments · 17 tracked
founders shown can be your intro pathBy year:2024 · 12021 · 12017 · 13 dated
Variantyx is a molecular diagnostics company offering genetic testing for rare genetic disorders, reproductive genetics, and precision oncology.
AI & Machine LearningBiotechDigital HealthHealthtechFramingham, US
Haim Neerman(Co-founder)inTomer Jackman(Co-founder & VP Customer Support and Lab Services)inJeffrey Weisberg(Chief Financial Officer)inYaron Rachmany(Operations, R&D, IT (executive))inChristine Stanley(Chief Genomics and Compliance Officer)inEyal Reinstein(Chief Medical Officer)in
Co-investorsBosch VenturesNew Era Capital PartnersOrbiMedPeregrine VenturesPitangoQuark Venture Inc.+2 more
Portable, connected precision-medicine platform for coagulation management.
PartnerHillel Bachrach· solo GP
HealthtechWaltham, US
Stephen J. Lemaster(Executive Officer)Mark J. Toland(Executive Officer, Director)David W. Long(Executive Officer)Jeffrey C Lightcap(Chairman)David W Long(Executive Officer)Michael Mashaal(Director)
PartnerHillel Bachrach· led
Co-investorsBioStar Ventures
Developing device-based therapies to treat neurodegenerative diseases such as ALS and PSP.
PartnerHillel Bachrach· solo GP
EnClear Therapies is a bio/med-tech company developing the EnTrega CSF platform, focused on cerebrospinal fluid-related therapies.
BiotechDigital HealthHealthtechMedical DevicesCambridge, US
Anthony DePasqua(Executive Officer, Director)inJason Camm(Director)Kasper Roet(Director)Tony DePasqua(President & CEO)Kevin Kalish(COO)Marcie Glicksman(VP Biology)
PartnerHillel Bachrach· led
Co-investorsFlucas VenturesTachyon VenturesVU Venture PartnersDolby Family Ventures
AI imaging platform for oncology care that tracks patient journeys and analyzes disease progression.
PartnerHillel Bachrach· solo GP
Medical diagnostic platform analyzing protein function for neurodegenerative disease and oncology, including a blood-based ALS diagnostic.
PartnerHillel Bachrach· solo GP
HealthtechNaperville, US
Matthew Pipke(Executive Officer, Director, Promoter)Gary Conkright(Executive Officer, Director, Promoter)
BoardRobert Lynch(Director)Edward Michael(Director)David Ormesher(Director)
PartnerHillel Bachrach· solo GP
UK IP development company creating medical diagnostic technologies analyzing protein/nucleic acid interactions.
PartnerHillel Bachrach· solo GP
Remedy Plan is a biopharmaceutical company developing drugs that target NAMPT, an essential enzyme dysregulated in more than 20 diseases including cancer.
BiotechHealthtechRockville, US
Gregory Plan Crimmins(Executive Officer, Director)
PartnerHillel Bachrach· solo GP
Co-investorsSchooner Capital
Biotech delivery company named a Fierce 15 biotech company.
PartnerHillel Bachrach· solo GP
Provider of dose and procedure-time reduction software for nuclear medicine; sold to Pharmalogic in 2019.
PartnerHillel Bachrach· solo GP
Verseau develops cancer immunotherapies based on macrophage repolarization, converting immuno-suppressive M2 macrophages into pro-inflammatory M1 macrophages to trigger an immune response against tumors.
BiotechHealthtechAuburndale, US
Walter Capone(Executive Officer)Christine Bunt(Executive Officer, Director)Daniel Anderson(Executive Officer, Director, Promoter)
BoardRobert Langer(Director, Promoter)Jong Chang(Director)
PartnerHillel Bachrach· led
Provider of digital radiography hardware and software solutions; acquired by Konica Minolta in 2015.
PartnerHillel Bachrach· solo GP
XR therapeutics platform company that merged with Amelia Virtual Care.
PartnerHillel Bachrach· solo GP
Co-investorsAsabys PartnersBridges IsraelFlying Tiger Capital
Zixi provides software for reliable video delivery over unpredictable IP networks, using patented hitless failover, multi-path bonding, and adaptive error correction to recover from packet loss.
Cloud ComputingMedia & EntertainmentSaaS
PartnerHillel Bachrach· led
Co-investorsSchooner Capital
Exits · 2
IPOs and acquisitions across the tracked portfolioViztekacq. by Konica MinoltaZixiacq. by Clearhaven Partners
Frequently asked questions
- How many investments has 20/20 HealthCare Partners LLC made?
- 20/20 HealthCare Partners LLC has 17 tracked investments, 2 of which have exited via acquisition or IPO.
- What stage does 20/20 HealthCare Partners LLC invest at?
- 20/20 HealthCare Partners LLC invests at the Seed, Series A, Growth, Late Stage stages.
- What sectors does 20/20 HealthCare Partners LLC focus on?
- 20/20 HealthCare Partners LLC focuses on AI & Machine Learning, Biotech, Digital Health, Healthtech, Media & Entertainment, Medical Devices.
- Where is 20/20 HealthCare Partners LLC located?
- 20/20 HealthCare Partners LLC is headquartered in Auburndale, US.
- Does 20/20 HealthCare Partners LLC lead rounds?
- Yes, 20/20 HealthCare Partners LLC leads investment rounds.
- Who does 20/20 HealthCare Partners LLC co-invest with?
- 20/20 HealthCare Partners LLC most often shares deals with Schooner Capital, Bosch Ventures, OrbiMed, among 12 tracked co-investors.
Images
Similar investors
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
Khosla Ventures is a venture capital firm that invests in early-stage companies focused on technology, mobile, and clean energy sectors, including biotechnology applications. The firm provides capital and strategic support to entrepreneurs developing breakthrough technologies across multiple markets.
Norwest is a venture and growth equity investment firm that has backed over 700 companies across sectors including AI, retail, and healthcare over its 65-year history.
A globally recognized venture capital firm designed to provide access to highly competitive venture deals to individual investors, consistently recognized for top-decile DPI performance and as one of the most active US venture firms.
New Alliance Capital is a Shanghai-based private equity and venture capital firm founded in 2008, focused on technology-driven sectors. Its backers include state-owned enterprise groups, insurance capital, fund-of-funds, government guidance funds, and listed companies.